ACC 23: The STELLAR Phase III Trial: Sotatercept in Patients With Pulmonary Arterial Hypertension

Подробнее о видео

Professor Marius Hoeper (Hannover Medical School, DE) joins us to outline the findings of the late-breaking STELLAR phase III trial.

The STELLAR Trial aims to study the safety and efficacy of sotatercept (MK-7962) and background pulmonary arterial hypertension (PAH) therapy in patients with PAH as compared to placebo. The investigators hypothesized that participants receiving sotatercept would have improved 6-minute walk distance at 24 weeks when compared to the placebo arm. 324 participants were enrolled in the trial.

Data presented in New Orleans showed that in patients with pulmonary arterial hypertension who were receiving stable background therapy, sotatercept resulted in a greater improvement in exercise capacity.

Questions:
-What is the background of this study?
-What was the patient population and study design?
-What are the key findings?
-What is the implication of these findings on both clinical practice, and future research?
-What further study is needed?

For more content from ACC.23/WCC head to Late-Breaking Science Video Collection.

Recorded on-site at ACC.23/WCC, New Orleans.

Visit Radcliffe Cardiology:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on Twitter: